1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Cancer Biology
  4. Volume 5, 2021
  5. Article

Annual Review of Cancer Biology

Volume 5, 2021

The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia

Abstract

Over the past several decades numerous preclinical and clinical studies have pursued new approaches for the treatment of acute myeloid leukemia (AML). While some degree of clinical response has been demonstrated for many therapies, for the most part, fundamental changes in the treatment landscape have been lacking. Recently, the use of the BCL-2 inhibitor venetoclax has emerged as a potent therapy for a majority of newly diagnosed AML patients. Venetoclax regimens have shown broad response rates with deep and durable remissions, with a superior toxicity profile compared with traditional intensive chemotherapy agents. Numerous ongoing studies are now using venetoclax in combination with a wide range of other agents as investigators seek even more effective and well-tolerated regimens. Notably, however, while the empirical results of BCL-2 inhibition are encouraging, the mechanisms that have led to these successful clinical outcomes remain unclear. Intriguingly, the activity of venetoclax in AML patients appears to go beyond simply modulating canonical antiapoptosis mechanisms; in addition, the efficacy of venetoclax is linked to its combined use with conventional low-intensity backbone therapies. This article will evaluate the state of the field, provide a summary of key considerations, and propose directions for future studies.

Keyword(s): AML, venetoclax, BCL-2, leukemia, metabolism
Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-060220-124048
2021-03-04
2025-04-22
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/5/1/annurev-cancerbio-060220-124048.html?itemId=/content/journals/10.1146/annurev-cancerbio-060220-124048&mimeType=html&fmt=ahah

Literature Cited

  1. Aimiuwu J, Wang H, Chen P, Xie Z, Wang J et al. 2012. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 119:5229–38
     [Google Scholar]
  2. Aldoss I, Yang D, Aribi A, Ali H, Sandhu K et al. 2018. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica 103:e404–7
     [Google Scholar]
  3. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D et al. 2014. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 28:1657–65
     [Google Scholar]
  4. Bonneau B, Prudent J, Popgeorgiev N, Gillet G 2013. Non-apoptotic roles of Bcl-2 family: the calcium connection. Biochim. Biophys. Acta 1833:1755–65
     [Google Scholar]
  5. Cancer Genome Atlas Res. Netw 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368:2059–74
     [Google Scholar]
  6. Chen J, Kao YR, Sun D, Todorova TI, Reynolds D et al. 2019. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat. Med. 25:103–10
     [Google Scholar]
  7. Chen X, Glytsou C, Zhou H, Narang S, Reyna DE et al. 2019. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov 9:890–909
     [Google Scholar]
  8. Cole A, Wang Z, Coyaud E, Voisin V, Gronda M et al. 2015. Inhibition of the mitochondrial protease ClpP as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 27:864–76
     [Google Scholar]
  9. Danial NN, Korsmeyer SJ. 2004. Cell death: critical control points. Cell 116:205–19
     [Google Scholar]
  10. de Boer B, Prick J, Pruis MG, Keane P, Imperato MR et al. 2018. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell 34:674–89.e8
     [Google Scholar]
  11. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS et al. 2020. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383:7617–29
     [Google Scholar]
  12. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M et al. 2019. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7–17
     [Google Scholar]
  13. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N et al. 2018. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am. J. Hematol. 93:401–7
     [Google Scholar]
  14. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S et al. 2020. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791–803
     [Google Scholar]
  15. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC et al. 2012. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481:506–10
     [Google Scholar]
  16. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B et al. 2011. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17:1086–93
     [Google Scholar]
  17. Gross A, Katz SG. 2017. Non-apoptotic functions of BCL-2 family proteins. Cell Death Differ 24:1348–58
     [Google Scholar]
  18. Gross A, McDonnell JM, Korsmeyer SJ 1999. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899–911
     [Google Scholar]
  19. Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR et al. 2016. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood 128:1671–78
     [Google Scholar]
  20. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334–36
     [Google Scholar]
  21. Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN et al. 2020. 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin. Cancer Res. 26:133371–83
     [Google Scholar]
  22. Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA et al. 2019. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood 134:4389–94
     [Google Scholar]
  23. Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R et al. 2018. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell 34:724–40.e4
     [Google Scholar]
  24. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP et al. 2006. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375–88
     [Google Scholar]
  25. Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL et al. 2017. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. PNAS 114:E7554–63
     [Google Scholar]
  26. Kuusanmaki H, Leppa AM, Polonen P, Kontro M, Dufva O et al. 2019. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105:3708–22
     [Google Scholar]
  27. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ et al. 2013. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12:329–41
     [Google Scholar]
  28. Leber B, Geng F, Kale J, Andrews DW 2010. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev. Mol. Med. 12:e28
     [Google Scholar]
  29. Lessene G, Czabotar PE, Colman PM 2008. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7:989–1000
     [Google Scholar]
  30. Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ et al. 2017. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov 7:1376–93
     [Google Scholar]
  31. Mirali S, Botham A, Voisin V, Xu C, St-Germain J et al. 2020. The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. Sci. Transl. Med. 12:538eaaz8264
     [Google Scholar]
  32. Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL et al. 2019. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov 9:910–25
     [Google Scholar]
  33. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ 1990. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 144:3602–10
     [Google Scholar]
  34. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L et al. 2014. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4:362–75
     [Google Scholar]
  35. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P et al. 2016. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374:2209–21
     [Google Scholar]
  36. Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M et al. 2020. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov 10:536–51
     [Google Scholar]
  37. Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S et al. 2018. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat. Med. 24:1859–66
     [Google Scholar]
  38. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M et al. 2010. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Investig. 120:142–56
     [Google Scholar]
  39. Sharon D, Cathelin S, Mirali S, Di Trani JM, Yanofsky DJ et al. 2019. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci. Transl. Med. 11:516eaax2863
     [Google Scholar]
  40. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM et al. 2014. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506:328–33
     [Google Scholar]
  41. Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X et al. 2011. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 20:674–88
     [Google Scholar]
  42. Sriskanthadevan S, Jeyaraju DV, Chung TE, Prabha S, Xu W et al. 2015. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood 125:2120–30
     [Google Scholar]
  43. Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D'Alessandro A et al. 2020. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nature Cancer In press. https://doi.org/10.1038/s43018-020-00126-z
    [Crossref] [Google Scholar]
  44. Tsujimoto Y. 1989a. Overexpression of the human BCL-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. PNAS 86:1958–62
     [Google Scholar]
  45. Tsujimoto Y. 1989b. Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene 4:1331–36
     [Google Scholar]
  46. Tsujimoto Y, Cossman J, Jaffe E, Croce CM 1985. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440–43
     [Google Scholar]
  47. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE et al. 2018. Functional genomic landscape of acute myeloid leukaemia. Nature 562:526–31
     [Google Scholar]
  48. van Galen P, Hovestadt V, Wadsworth MH 2nd, Hughes TK, Griffin GK et al. 2019. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176:1265–81.e24
     [Google Scholar]
  49. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ et al. 2012. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151:344–55
     [Google Scholar]
  50. Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J et al. 2020. Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood 135:242137–45
     [Google Scholar]
  51. Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL et al. 2019. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J. Clin. Oncol. 37:1277–84
     [Google Scholar]
  52. Yogarajah M, Stone RM. 2018. A concise review of BCL-2 inhibition in acute myeloid leukemia. Expert Rev. Hematol. 11:145–54
     [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-060220-124048
Loading
The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia
Annual Review of Cancer Biology 5, 277 (2021); https://doi.org/10.1146/annurev-cancerbio-060220-124048
/content/journals/10.1146/annurev-cancerbio-060220-124048
/content/journals/10.1146/annurev-cancerbio-060220-124048
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error